Improving insulin sensitivity and glucose homeostasis are essential for managing MASH and MASLD, and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) play a critical role in this process [224]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.